Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Incidence is increasing for six of 12 obesity-related cancers, including colorectal, kidney and pancreatic.
Urging all Americans to give their kidneys a second thought and a well-deserved checkup.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
Women with the chronic condition are 6 percent more likely than men to develop cancer.
Sidharth Ghosh is an IT professional, sportsman and kidney cancer survivor in Delhi, India.
Two years later, Michael Mullan’s cancer is still at bay because of immunotherapy and targeted chemotherapy.
Immunotherapy combo was more effective and better tolerated for first-time treatment.
Are immunotherapy and targeted therapies ready to replace toxic chemotherapy?
The FDA previously approved Cabometyx in 2016 for treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.